|1.||Lavin, F Martin: 1 article (10/2004)|
|2.||Hosokawa, Kazuyuki: 1 article (10/2004)|
|3.||Chen, Philip: 1 article (10/2004)|
|4.||Bottle, E Steven: 1 article (10/2004)|
|5.||Tada, M: 1 article (04/2001)|
|6.||Ogata, T: 1 article (04/2001)|
|7.||Ito, T: 1 article (04/2001)|
|8.||Saito, K: 1 article (04/2001)|
|9.||Yoshioka, H: 1 article (04/2001)|
|10.||Tanizawa, H: 1 article (04/2001)|
04/01/2001 - "The strongest spot of CPROXYL was observed on ESR images, showing the accumulation at the bladder, while the spot of TEMPO-DX was observed in the solid tumor of the back of the mouse. "
04/01/2001 - "Using continuous intravenous injection, CPROXYL was also rapidly excreted, but it was confirmed that TEMPO-DX concentrated in tumor tissue because it has a long half-life in vivo. "
04/01/2001 - "Imaging of a tumor with ESR was tried using two different types of spin probes, a low molecular weight spin probe, CPROXYL, and a polymer spin probe, TEMPO-DX. "
|2.||Ataxia Telangiectasia (Louis Bar Syndrome)
10/01/2004 - "Three water-soluble carboxy nitroxide antioxidants, 5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl, 4-carboxy-2,2,6,6-tetramethylpiperidin-1-yloxyl, and 3-carboxy-2,2,5,5-tetramethylpyrrolidin-1-yloxyl, show significant impact on the postirradiation survival rates of ataxia telangiectasia (A-T) cells compared to normal cells, an assay which represents a model for understanding the impact of ROS damage on the A-T phenotype. "
|3.||5- carboxy- 1,1,3,3- tetramethylisoindolin- 2- yloxyl
|4.||2,2,6,6- tetramethylpiperidine- 1- oxyldextran